Algen Biotechnologies

Emerging

AI drug discovery platform mapping functional gene networks for novel target identification; $12.63M from Viking Global and YC W20 applying computational genomics to decode disease biology.

Updated March 2026

Company Overview

About Algen Biotechnologies

Algen Biotechnologies is a San Francisco-based drug discovery company that builds computational platforms to decode functional gene networks — using machine learning and genomic data to map the relationships between genes, understand how gene interactions drive disease, and identify novel therapeutic targets that traditional drug discovery approaches miss because they analyze genes in isolation. Founded in 2018 by Chun Hao Huang and Christine Du and a Y Combinator W20 graduate, Algen raised $12.63 million total including a $9 million Seed VC-II round led by Viking Global Investors in February 2022.

Business Model & Competitive Advantage

Algen's platform addresses a fundamental limitation in genomics-based drug discovery: most genetic analysis identifies individual disease-associated genes, but biology operates through networks — a gene's functional impact depends on which other genes it interacts with, which pathways are co-activated, and the cellular context. Algen's functional genomics platform maps these network relationships from large-scale genetic perturbation data, identifying which gene combinations drive disease phenotypes and which targets are central to therapeutic intervention.

Competitive Landscape 2025–2026

In 2025, Algen Biotechnologies competes in the AI drug discovery and computational genomics space with Recursion Pharmaceuticals (RXRX, AI-driven drug discovery), Schrödinger (computational chemistry and biology), Insitro, and academic-spinout gene network platforms for computational drug target identification. The AI drug discovery space has attracted significant investment — Recursion went public, Isomorphic Labs (DeepMind spinout) signed major pharma deals — validating the thesis that computational approaches can accelerate target identification and candidate selection. Viking Global's investment reflects institutional conviction in Algen's gene network approach. The 2025 strategy focuses on advancing lead therapeutic programs from the computational platform into experimental validation, building pharma partnerships for target licensing, and growing the platform's applicability across oncology, neurodegeneration, and metabolic disease.

Revenue
$12.63M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

Algen Biotechnologies is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Not So Random Others

Yoneda Labs

Healthcare
HealthtechB2bNorth America

Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit

Decoda Health

Healthcare
HealthtechAi PoweredAutomationNorth America

Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap

Fortuna Health

Healthcare
HealthtechB2bAi PoweredAutomationNorth America

Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi

Brisk

Consumer Food & Beverage
B2cManufacturingNorth AmericaFortune500

Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione

Altria

Consumer Goods
B2cManufacturingNorth AmericaPublicFortune500

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s

AbbVie

Healthcare
AnalyticsB2bEnterpriseGlobalHealthtechPublic

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp

For Algen Biotechnologies

Claim This Profile

Are you from Algen Biotechnologies? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Algen Biotechnologies Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Algen Biotechnologies vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →